Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

topoisomerase I/II inhibitor NEV-801

A multi-targeted agent with potential antineoplastic activity. Upon administration, NEV-801 appears to selectively inhibit topoisomerase (Topo) I and II, and activates hypoxia-inducible factor 1 (HIF-1) transcription and the expression of vascular endothelial growth factor (VEGF) mRNA. NEV-801 is also able to overcome multidrug resistance (MDR) 1-mediated resistance.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	TopI/II NEV-801
Code name:	NEV-801 NEV801

topoisomerase I/II inhibitor NEV-801

Search NCI's Drug Dictionary